676560-83-1

Basic information

• Product Name: (2S,5S)-1-tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate
• Synonyms: (2S,5S)-1-tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate;(2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester;1-(tert-butyl) 2-ethyl (2S,5S)-5-methylpyrrolidine-1,2-dicarboxylate
• CAS NO: 676560-83-1
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.32602
• Mol File: 676560-83-1.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S,5S)-1-tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5S)-1-tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate(676560-83-1)
• EPA Substance Registry System: (2S,5S)-1-tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate(676560-83-1)

Safety Data

• Hazardous Substances Data: 676560-83-1(Hazardous Substances Data)

Usage

General Description

The chemical (2S,5S)-1-tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate is a compound with the molecular formula C15H27NO4. It has a pyrrolidine ring structure with two carboxylate groups attached to it. The compound also contains a tert-butyl group, an ethyl group, and a methyl group. This chemical is commonly used in the field of organic synthesis and drug development due to its potential pharmaceutical properties. It may have applications in the synthesis of various drugs and pharmaceutical compounds. Additionally, it can also be used as a building block in organic chemistry to create new compounds for research and development purposes.

Upstream product

• 676560-85-3 (2S,5S)-ethyl 5-methylpyrrolidine-2-carboxylate 2,2,2-trifluoro acetate salt 
• 24424-99-5 di-tert-butyl dicarbonate 
• 896733-29-2 (S)-5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylic acid ethyl ester 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 913251-58-8 (S)-2-(tert-butoxycarbonylamino)-5-oxohexanoic acid ethyl ester 
• 676560-84-2 (2S,5S)-5-methylpyrrolidine-2-carboxylic acid ethyl ester 

Downstream Products

• 1433280-49-9 4-(4-bromo-phenyl)-2-((2S,5S)-5-methyl-pyrrolidin-2-yl)-1H-imidazole 
• 1250939-12-8 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester 
• 1250939-15-1 (2S,5S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-5-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1378390-49-8 ((S)-1-{(2S,5S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-5-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1433280-50-2 [(S)-2-methyl-1-((2S,5S)-2-methyl-5-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]carbamic acid methyl ester 
• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1844064-96-5 (2S,4S)-2-[5-(2-{(2S,4S)-1-{N-(methoxycarbonyl)-L-valyl}-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromene[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine 
• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1335316-40-9 (2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carboxylic acid 

Relevant articles and documents

Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof

The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.

PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS

The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.